Jan 19, 2021 | Press Releases
Using Molecular Dynamic (MD) simulation, ImmunityBio scientists assessed the affinity of mutated spike receptor binding domain (RBD) of SARS-CoV-2 to its receptor on human cells, ACE2 The mutations studied occur in the new UK and South African strains that have spread...
Jan 19, 2021 | Press Releases
Plans to study COVID-19 subcutaneous and oral, room-temperature capsule vaccineto protect against escape mutants ImmunityBio to conduct initial trial of its human adenovirus (hAd5) COVID-19 vaccine candidate in South Africa, where the 501Y.V2 strain has been recently...
Jan 13, 2021 | Press Releases
Pivotal QUILT 88 trial based on combination immunotherapy of “Cancer Moonshot” strategy; early indications of increased survival rate for pancreatic cancer patients with no other approved treatment options In initial Cancer Moonshot QUILT trials of haNK and avelumab...
Jan 6, 2021 | Press Releases
EL SEGUNDO, Calif., January 6, 2021 — NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Dr. Patrick Soon-Shiong M.D., Executive Chairman of the Board of Directors, will participate in the 39th Annual...
Jan 4, 2021 | Press Releases
Detailed computer modeling, completed in partnership with Microsoft, explains virulence of COVID-19 and provides key information that may lead to a better understanding of the multiple mutations currently occurring to the “spike” protein as the virus evolves...
Dec 30, 2020 | Press Releases
Dr. Benedetti Brings More Than 20 Years in Oncology Clinical Development and Global Large Pharma Experience CULVER CITY, Calif., December 30, 2020 – ImmunityBio, Inc., a privately-held immunotherapy company, today announced that it has appointed Fabio M. Benedetti,...
Dec 21, 2020 | Press Releases
QUILT 3.032 study completes planned enrollment of BCG unresponsive non-muscle invasive bladder cancer CIS cohort with 59% probability of patients maintaining complete response for at least 12 months Over 85% of patients in this study have avoided a cystectomy to date...
Dec 21, 2020 | Press Releases
Merged entity brings together 11 Phase II / III clinical trials across oncology and infectious disease that use combined immunotherapy platforms Broad late-stage pipeline for solid tumors including bladder, lung, breast, and pancreatic in addition to infectious...
Dec 10, 2020 | Press Releases
BARDA-sponsored study shows second-generation hAd5 vaccine candidate in both subcutaneous and room temperature oral formulations inhibits SARS-CoV-2 virus replication to undetectable levels and clears infection within days in 100% of vaccinated non-human primates The...
Nov 10, 2020 | Press Releases
First two cohorts fully enrolled; Low dose cohort reports no serious adverse events (SAEs), high dose cohort safety analysis ongoing Subject screening is ongoing for Phase I expansion cohorts Phase 2 / 3 hAd5 COVID-19 trial in design CULVER CITY & EL SEGUNDO,...
